Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss

v3.21.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Condensed Consolidated Statements of Comprehensive Loss [Abstract]        
Collaborations revenue $ 489 $ 0 $ 589 $ 0
Operating expenses:        
General and administrative 1,595 565 6,707 1,508
Research and development 3,126 1,383 10,437 2,311
Acquired in-process research and development 0 0 0 2,126
Total operating expenses 4,721 1,948 17,144 5,945
Loss from operations (4,232) (1,948) (16,555) (5,945)
Interest expense 0 (179) 0 (1,422)
Fair value change of warrant liability and premium conversion derivatives 0 879 (33,829) 158
Gain on note extinguishment 0 0 0 1,260
Other income, net 2 0 4 9
Loss before income taxes (4,230) (1,248) (50,380) (5,940)
Benefit (provision) for income taxes 0 0 0 0
Net loss (4,230) (1,248) (50,380) (5,940)
Other comprehensive loss, net of tax 0 0 0 0
Comprehensive loss $ (4,230) $ (1,248) $ (50,380) $ (5,940)
Net loss per share:        
Basic (Note 11) (in dollars per shares) $ (0.25) $ (0.33) $ (3.64) $ (1.61)
Diluted (Note 11) (in dollars per shares) $ (0.25) $ (0.33) $ (3.64) $ (1.61)
Number of shares used in per share calculations:        
Basic (in shares) 16,925,006 3,743,907 13,841,067 3,678,840
Diluted (in shares) 16,925,006 3,743,907 13,841,067 3,678,840